Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...

Leerink Partners reiterated their market perform rating on shares of 2seventy bio (NASDAQ:TSVT – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. The brokerage ...

Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

In a report released today, Daina Graybosch from Leerink Partners downgraded 2seventy bio (TSVT – Research Report) to a Hold, with a price ...

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

Walgreens Boots Alliance says it has agreed to be acquired by the private equity firm Sycamore Partners as the struggling ...

Fintel reports that on March 7, 2025, Leerink Partners initiated coverage of CorMedix (NasdaqGM:CRMD) with a Outperform ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on 908 Devices (MASS – Research Report), with a ...

Equities researchers at Leerink Partnrs reduced their FY2025 earnings estimates for ICON Public in a research report issued ...